Sign inJoin free

Watch / CEOs & MDs

Immutep gets FDA boost

26 July 202410:14

Immutep gets FDA boost

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Marc Voigt, the CEO of Immutep (ASX: IMM), offers optimism on the success of their drug therapy designed to combat lung cancer. The therapy recently received positive feedback from US Federal Drug Administration, a significant step towards achieving approval. This approval would allow the company to embark on a critical clinical trial registration against non small-cell lung cancer. Marc further points out that they have collaborated with Merck Pharma, using their top-selling drug, Keytruda, for the clinical trial.

Marc delves into the details of the trial, explaining that it involves two groups of lung cancer patients. Both groups will receive Keytruda and chemotherapy, with one group also receiving Immutep's (ASX: IMM) drug as an addition. This stage of the trial aims to gather evidence of the drug's efficacy, using a double-blind procedure to avoid bias. Marc contrasts this trial to a previous one that was undertaken in June, indicating that the trial's purpose is to identify patient populations where the drug can be effective.

Additionally, Immutep (ASX: IMM) is exploring antibody therapy for autoimmune diseases, with another trial set in the Netherlands. Marc informs us that they are working alongside a specialised institute in this case. This trial's objective is to determine the safety and effectiveness of the drug, IMP 761, against more than 90% of autoimmune diseases. Furthermore, collaborations with Novartis and an early stage program are in the pipeline, which Marc emphasises that investors should expect significant developments.

Full unedited transcript below:

0:00

Well. Aussie Biotech Limited has got positive feedback from the US FDA for its drug therapy to trick lung cancer. The company is also beginning a phase one clinical trial in the Netherlands to test its new antibody therapy for autoimmune diseases. Let's get into all the detail with Imhotep chief executive Mark Boyd, who joins us now. Mark, good to see you again. Good to see you, Andrew. All right. Let's begin first with the FDA and that approval. What does that actually amount to then? Yeah. First of all, it's important when you start a decisive clinical trial registration trial in the largest cancer indication, first line non-small cell lung cancer, um, where you have high unmet medical need, you talk with the regulators. And the most important regulators in the world is the FDA. Um, and then you get regulatory clearance for your strategic setup. Actually, we teamed up for this clinical trial with us, Merck Pharma giant, which is a top selling drug in the industry called

0:59

Keytruda, and combine it with our flag mode and 750 patient clinical trial. Our phase three should be better discussed with the regulators who would later on improve your drug. This is what we did and we have been getting very, very positive feedback. Okay, so the next phase then in terms of the trial is what setting it up with, looking at the efficacy of your drug combined with that of Merck's Keytruda and what obviously compared with placebo, if you like, is is it not quite because on the one hand side, you have two ARM clinical trials or two groups of patients. Both groups of patients will receive Keytruda and chemotherapy, and one group of the patients will receive free Mod on top of that and the other one will receive placebo. So it's a so-called double blind clinical trial. It's a state of the art clinical exercise with a clear aim to get regulatory approval.

1:57

How does this differ from that previous trial you had which the results weren't well received? Um, in terms of that, that earlier one, that what was a few months ago, was it or earlier in the year? Yeah, that was in uh, actually not that long ago, end of June. Okay. We had, uh, positive results in head and neck cancer. So a different disease in one group of patients, it was, uh, inconclusive, but overall, a positive clinical trial, which is actually still running. Uh, so the jury is still out there. If we can deliver on overall survival, that's the most important endpoint for the patients and for the regulators and health care insurances. If we can deliver there and had a neck cancer, the jury is still out there. I believe we have a good chance. But it differs in terms of trial size and trial nature. The trial and had the net cancer is a phase two. This is typically a trial which is designed to identify patient population where the drug can work, so that you better

2:57

can design a phase three clinical trial tactic for the trial. And first, like non-small cell lung cancer is 750 patient clinical trial, which is designed to show statistical significance and to get approval and have the drug on the market. That's the final classical step if the trial is successful before getting on the market. The other trial, in contrast, just looking at the sample size, has a round about 171 patients. So a big difference.

3:29

Additional to that, as I mentioned at the top, they're also looking at this trial in regards to antibody therapy for autoimmune diseases. Yes, indeed. We are a multiple product company and a completely separate product called IMP 761 will enter clinical development relatively soon. We have regulatory clearance in the Netherlands and a specialized institute in Leiden. And there we look at autoimmune diseases. Conceptually, our drug can address more than 90% of autoimmune diseases. We will go first in men. So safety is of course a very important endpoint here. But also we will look at the biological activity of the drug. So you can already conclude about the activity of the drug in terms of inflammation, autoimmune diseases. Because unlike in oncology where you would like to have an active immune system, here we would like to down modulate the immune system

4:29

and it will not take long. Apologies. It will not take long until we see results first. Results come to the end of the year and some more first half of next year. Why is that being conducted in the Netherlands? Because there's a specialized institute. When you start a clinical trial in autoimmune diseases, unlike an oncology, you start with healthy volunteers. And if you would like to read into the biology of the drug, you have to have specialized, um, essays and specialized methods to detect this biological activity. What we do there is to irritate the skin of a patient, cause some local inflammation, and then give either placebo so it's a blinded phase one trial, either placebo or the drug. And then to measure the difference and the effect size. And it's a world class institute. They are specialized that

5:21

any other drug candidates in the works at the moment are. Yes, indeed. We have one collaboration with Novartis regarding a classical so-called immune checkpoint inhibitor. They are running the clinical trials. We have another program in early stage small molecule, the dream of a pill of an immune checkpoint inhibitor. These are the drugs which are making billions of dollars. And if you can change the formulation so that you can take it as a pill and not an intravenous procedure, that would be perfectly fine. So a lot to expect in the short, medium and long term. As Mark investors would know, human trials are expensive. So how are you funding this? How is your balance sheet looking at the moment? We have a very strong balance sheet. We have on a pro forma level, close to 200 million AUD cash on bank. Um, we have a very supportive shareholder base. Um, and also, in light of the recent share price movements, we are very thankful for that.

6:21

And, um, I think it's great that we have to turn the company effectively into a phase three company, the most important market in oncology, together with the strongest brand. And that we have also clearing the way with the FDA.

6:38

So which trial is most promising at this point? Is that what you're focused on is the the one with the phase three clinical trial given where you are with the FDA?

6:49

That's, um, the most advanced clinical trial, that's the most robust clinical trial. And clearly, if you look at the market size, the highest value proposition, however, we have the trial and hidden cancer continuing. You will see actually more data, uh, in the remainder of this year and also in the first half of next year. So that trial is continuing. We will continue to deliver data. We have another trial in metastatic breast cancer phase two three. Um, and we have other smaller trials and soft tissue sarcoma or cellular cancer. So we um designed a portfolio and created a portfolio of different clinical trials,

7:28

as you. Let's assume that you're a successful here. What is the timeline, particularly as far as that phase three with your, uh, your feet combined with Merck's Keytruda? What, beyond this trial, what happens next? What's the timeline as you would look to commercialization if we're successful? Yeah. First of all, we will start the trial back end of this early next year. We will certainly have assume round about 150 hospitals around the globe in many different countries, including Australia. That's the plan. The trial should be fully recruited by mid 26. We will have the first readout by the end of 25. It's of course dependent on the events and the recruitment and then an interim analysis back end of 26 on which we could potentially, if positive, sufficiently positive on which we can file.

8:21

My biotech tends to be a very binary outcomes as far as these trials are concerned. And therefore it can be very difficult for investors, uh, to stump up money as a result. Um, how do you get it? How do you get across that? How do you get encourage investors to actually back you in those terms, given it is very hit and miss?

8:45

Indeed, there are clinical trials which can cause a binary event. That is definitely true. And there are some companies which have one product, one clinical trial. So first of all, you have a portfolio of different products, different clinical trials. And if you look at the clinical trial as such, let's take the head and neck one, because it has been causing some some waves in the share price. And first of all, the negative reaction. And the trial is designed in a way that it can show success in different groups of patients. So you design a trial in the best case that you are not looking at the binary outcome overall, but that you have different chances, different shots on goal if you like, for different groups of patients. And even Keytruda top selling drug in the world 25 billion and you will sales in terms of US dollars even this powerful drug for instance and had a neck cancer. It's not approved for a certain group of patients where we have been recently showing very good results. July 11th first

9:45

Australian company delivering a so-called small plenary.

9:49

conference. Where our track has been discussed. So you try to spread the risk across different products, different clinical trials and on the clinical trial level across different groups of patients. It's by no means full guarantee for success, but you try in a responsible manner, design your trials and your programs in the right way, that you can maximize the chances of the product to shine in the right group of patients.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy